Table 4.
Phase II clinical trials of neoadjuvant immunochemotherapy.
| Trial | Stage | Size | Intervention Used | ORR | MPR | pCR | Survival |
|---|---|---|---|---|---|---|---|
| NADIM (NCT03081689) [37] |
IIIA, N2 | 46 | Nivolumab + Paclitaxel, carboplatin |
78% | 83% | 71% | OS at 24 months: 89.9% |
| TOP1201 (NCT01820754) [45] |
IB–IIIA | 24 | Ipilimumab (cycles 2–3 only) Paclitaxel Cisplatin (or carboplatin) |
58% | NR | 15% | OS at 24 months: 73.0% |
| MAC (NCT02716038) [46] |
IB–IIIA | 30 | Atezolizumab + Nab-paclitaxel, carboplatin |
63% | 57% | 33% | mDFS: 17.9 months |
| CheckMate816 (NCT02998528) [47] | IB–IIIA | 350 | Chemotherapy + nivolumab vs. chemotherapy | NR | 36.9% vs. 8.9% | 24% vs. 2.2% | NR |
| Duan, H. [48] | IIA–IIIB | 23 | Chemotherapy + PD-1 inhibitor | 73.9% | 50% | 30% | mPFS: 11.3% |
| Shen, D. [49] | IIB–IIIB | 37 | Chemotherapy + pembrolizumab | 86.5% | 64.9% | 45.9% | NR |
ORR, objective response rate; MPR, major pathological response; pCR, pathological complete response; mDFS, median disease-free survival; OS, overall survival; PD-1, programmed cell death protein 1.